BioCryst Pharmaceuticals, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2011.
Excerpt from:
BioCryst Reports Fourth Quarter and Full Year 2011 Financial Results
BioCryst Reports Fourth Quarter and Full Year 2011 Financial Results
February 16, 2012 By
BioCryst hep C drug shows promise, shares jump
February 15, 2012 By
(Reuters) – BioCryst Pharmaceuticals Inc said its experimental hepatitis C drug showed promise in preclinical studies, sending its shares up as much as 16 percent to their highest in more than seven months. Additional non-clinical experiments on the drug are ongoing or planned, the company said in a statement on Wednesday. BioCryst, which is also testing potential cancer, influenza and gout …
Excerpt from:
BioCryst hep C drug shows promise, shares jump
BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout
January 8, 2012 By
BioCryst Pharmaceuticals, Inc. today announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid therapeutic goal of
Taken from:
BioCryst Announces Positive Results from Its Ongoing BCX4208 Phase 2B Study in Patients with Gout
BioCryst Experimental Gout Drug Helps Patients in Trial
November 8, 2011 By
BioCryst Pharmaceuticals Inc. (BCRX) gained as much as 8.3 percent after a study showed that adding the drugmaker’s gout medicine to a standard therapy lowered patients’ uric acid levels better than the usual treatment.
Follow this link:
BioCryst Experimental Gout Drug Helps Patients in Trial
New results from BioCryst’s BCX4208 Phase 2b gout study
November 8, 2011 By
BioCryst Pharmaceuticals, Inc. presents new results today from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinically important serum uric acid (sUA) goal of
Read the original:
New results from BioCryst’s BCX4208 Phase 2b gout study
BioCryst Pharmaceuticals Announces New BCX4208 Gout Data Has Been Accepted as a Late-Breaker Oral Presentation at the …
October 24, 2011 By
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from its Phase 2b …
BioCryst says gout drug worked in mid-stage trial
October 5, 2011 By
BioCryst Pharmaceuticals Inc.
Read More:
BioCryst says gout drug worked in mid-stage trial
BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to …
October 5, 2011 By
BioCryst Pharmaceuticals, Inc.
See more here:
BioCryst Announces Positive Top-Line Results from BCX4208 Phase 2B Gout Study in Patients Not Responding to …
BioCryst invests more in R&D
May 24, 2011 By
Drug company BioCryst Pharmaceuticals has upped its bet on its experimental gout medicine as part of a $5 million increase in this year’s research-and-development budget.
See the article here:
BioCryst invests more in R&D
BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology
April 22, 2011 By
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the presentation of clinical results …
Original post:
BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology
